Advertisement

Tailoring adjuvant chemotherapy by circulating tumor DNA (ctDNA) in older patients with stage II-III colon cancer

Published:August 26, 2022DOI:https://doi.org/10.1016/j.jgo.2022.08.016

      Abstract

      In most western countries, the median age of patients with CRC is around 70 years. Although the benefit of adjuvant chemotherapy has been established in stage III colon cancer, it remains controversial in patients with stage II disease. Colon cancer treatment in older adults follows the same basic concepts as in younger patients. However, for older patients, who may have age-related organ function decline and comorbid conditions that may limit life expectancy, special attention must be paid to the risks of chemotherapy, including treatment-related toxicities and quality of life issues. Long-term toxicities are particular concerns in older patients who received adjuvant chemotherapy. In the high-risk frail patient population, avoiding adjuvant therapies in patients with negative circulating tumor DNA (ctDNA) group, could prevent treatmentrelated toxicities while preserving the quality of life. In the treatment paradigm of earlystage colon cancer, the promise of ctDNA lies in its potential to detect minimal residual disease following resection of the primary tumor, allowing precise risk assessment and ctDNA-guided adjuvant therapy. Future studies will determine whether this technique may tailor treatment for patients in the adjuvant setting. Subgroup analyses by age may yield data on the use of ctDNA in older patients. Integration of the ctDNA approach to geriatric assessment may complete the missing piece of the puzzle when making adjuvant treatment decisions in older patients with colon cancer.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Geriatric Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Arnold M.
        • et al.
        Global patterns and trends in colorectal cancer incidence and mortality.
        Gut. 2017; 66: 683-691
        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2016.
        CA Cancer J Clin. 2016; 66: 7-30
        • Benson A.B.
        • et al.
        Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology.
        J Natl Compr Cancer Netw. 2021; 19: 329-359
        • Shah M.A.
        • et al.
        Impact of patient factors on recurrence risk and time dependency of oxaliplatin benefit in patients with colon cancer: analysis from modern-era adjuvant studies in the adjuvant colon cancer end points (ACCENT) database.
        J Clin Oncol. 2016; 34: 843
        • Labianca R.
        • et al.
        Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2013; 24 (vi64-72)
        • Millan M.
        • et al.
        Treatment of colorectal cancer in the elderly.
        World J Gastrointest Oncol. 2015; 7: 204
        • Hoshino N.
        • et al.
        Impact of venous invasion on the efficacy of adjuvant chemotherapy in elderly patients with stage III colorectal cancer.
        Med Oncol. 2017; 34: 1-6
        • Nitsche U.
        • Stöss C.
        • Friess H.
        Effect of adjuvant chemotherapy on elderly colorectal cancer patients: lack of evidence.
        Gastroint Tumors. 2017; 4: 11-19
        • Holm M.
        • et al.
        Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing.
        PLoS One. 2020; 15e0239819
        • Raja R.
        • et al.
        Early reduction in ctDNA predicts survival in patients with lung and bladder Cancer treated with Durvalumab.
        Clin Cancer Res. 2018; 24: 6212-6222
        • Xu R.H.
        • et al.
        Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma.
        Nat Mater. 2017; 16: 1155-1161
        • Chen M.
        • Zhao H.
        Next-generation sequencing in liquid biopsy: cancer screening and early detection.
        Hum Genomics. 2019; 13: 1-10
        • Cheng F.T.-F.
        • et al.
        Liquid biopsy detects relapse five months earlier than regular clinical follow-up and guides targeted treatment in breast cancer.
        Case Rep Oncol Med. 2019; https://doi.org/10.1155/2019/6545298
        • Reinert T.
        • et al.
        Analysis of plasma cell-free DNA by Ultradeep sequencing in patients with stages I to III colorectal Cancer.
        JAMA Oncol. 2019; 5: 1124-1131
        • Tarazona N.
        • et al.
        Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
        Ann Oncol. 2019; 30: 1804-1812
        • Tie J.
        • et al.
        Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer.
        JAMA Oncol. 2019; 5: 1710-1717
        • Gill S.
        • et al.
        Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?.
        J Clin Oncol. 2004; 22: 1797-1806
        • André T.
        • et al.
        Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
        J Clin Oncol. 2009; 27: 3109-3116
        • Sargent D.J.
        • et al.
        A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.
        N Engl J Med. 2001; 345: 1091-1097
        • Sanoff H.K.
        • et al.
        Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.
        J Clin Oncol. 2012; 30: 2624
        • Kuebler J.P.
        • et al.
        Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
        J Clin Oncol. 2007; 25: 2198-2204
        • McCleary N.J.
        • et al.
        Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database.
        J Clin Oncol. 2013; 31: 2600
        • Haller D.
        • et al.
        Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials.
        Ann Oncol. 2015; 26: 715-724
        • Papamichael D.
        • et al.
        Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013.
        Ann Oncol. 2015; 26: 463-476
        • Dotan E.
        • et al.
        Challenges in the management of older patients with colon cancer.
        J Natl Compr Cancer Netw. 2012; 10 ([quiz 225]): 213-224
        • Wildiers H.
        • et al.
        International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer.
        J Clin Oncol. 2014; 32: 2595-2603
        • Extermann M.
        • et al.
        Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy risk assessment scale for high-age patients (CRASH) score.
        Cancer. 2012; 118: 3377-3386
        • Hurria A.
        • et al.
        Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study.
        J Clin Oncol. 2011; 29: 3457
        • Angeli E.
        • et al.
        Development, validation and clinical impact of a prediction model for 6-month mortality in older cancer patients: the GRADE.
        Aging (Albany NY). 2020; 12: 4230-4246
        • Ferrat E.
        • et al.
        Performance of four frailty classifications in older patients with Cancer: prospective elderly Cancer patients cohort study.
        J Clin Oncol. 2017; 35: 766-777
        • Bardia A.
        • et al.
        Adjuvant chemotherapy for resected stage II and III colon cancer: Comparison of two widely used prognostic calculators.
        in: Seminars in oncology. Elsevier, 2010
        • Papamichael D.
        • et al.
        Validity of adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database.
        J Geriatr Oncol. 2016; 7: 422-429
        • Guven D.C.
        • et al.
        A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer.
        Crit Rev Oncol Hematol. 2021; 168103528
        • Berger A.W.
        • et al.
        Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA.
        PLoS One. 2017; 12e0174308
        • Diehl F.
        • et al.
        Circulating mutant DNA to assess tumor dynamics.
        Nat Med. 2008; 14: 985-990
        • Osumi H.
        • et al.
        Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer.
        Sci Rep. 2019; 9: 17358
        • Tie J.
        • et al.
        Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.
        Sci Transl Med. 2016; 8: 346ra92
        • Tie J.
        • et al.
        Circulating tumor DNA analysis guiding adjuvant therapy in stage II Colon Cancer.
        N Engl J Med. 2022; 386: 2261-2272https://doi.org/10.1056/NEJMoa2200075
        • Papamichael D.
        • et al.
        Adjuvant chemotherapy in patients with colorectal cancer. Is there a role in the older adult?.
        Eur J Surg Oncol. 2020; 46: 363-368
        • Bent A.
        • et al.
        The future of ctDNA-defined minimal residual disease: personalizing adjuvant therapy in CRC.
        Clin Colorectal Cancer. 2022; 21: 85-89https://doi.org/10.1016/j.clcc.2022.03.004